How vaccines work against COVID-19: Science, Simplified

After we have been exposed to an infection, our immune system remembers the threat, in particular by producing antibodies. These are proteins that circulate in the blood and throughout the body; they quickly recognize and disable the invader upon contact, thereby preventing or minimizing illness. This is why we usually do not get sick with the same bug twice; we are immune. Vaccines mimic this process, encouraging the immune system to make antibodies without us having to go through the illness.

Some of the leading SARS-CoV-2 vaccine candidates are “mRNA vaccines,” based on incorporating the genetic blueprint for the key spike protein on the virus surface into a formula that when injected into humans instructs our own cells to make the spike protein. In turn, the body then makes antibodies against the spike protein, and they protect us against viral infection.
This strategy is faster than more traditional approaches, which often involve generating weakened or inactivated forms of a live virus, or making large amounts of the spike protein to determine whether they can prompt an antibody response.

Once a potential vaccine is discovered, a number of checkpoints exist before it can be administered to people. First are preclinical tests, which involve experiments in a laboratory and with animals. Scientists must ensure the vaccine candidate is not only effective, but also safe. For example, an antibody response to an imperfect vaccine could, under extremely rare circumstances, end up increasing the danger of becoming infected.
When the potential vaccine achieves the necessary preclinical results, clinical trials can begin in a small group of people. As the vaccine candidate advances, it is tested on increasing numbers of people, with scientists and doctors closely monitoring safety, efficacy and dosing. Upon successful completion of clinical trials, the vaccine candidate must be reviewed and approved by regulatory agencies, such as the FDA, before large-scale manufacturing and distribution gets underway and the licensed vaccine is administered widely.

After we have been exposed
to an infection,

our immune system remembers the threat,

in particular by producing antibodies.

These are proteins that circulate
in the blood and throughout the body;

they quickly recognize and disable
the invader upon contact,

thereby preventing or minimizing illness.

This is why we usually do not get sick
with the same bug twice;

we are immune.

Vaccines mimic this process,

encouraging the immune system
to make antibodies

without us having to go
through the illness.

Some of the leading
SARS-CoV-2 vaccine candidates

are "mRNA vaccines,"

based on incorporating
the genetic blueprint

for the key spike protein
on the virus surface

into a formula

that when injected into humans,

instructs our own cells
to make the spike protein.

In turn, the body then makes antibodies
against the spike protein,

and they protect us
against viral infection.

This strategy is faster
than more traditional approaches,

which often involve generating weakened
or inactivated forms of a live virus,

or making large amounts
of the spike protein

to determine whether they can prompt
an antibody response.

Once a potential vaccine is discovered,

a number of checkpoints exist
before it can be administered to people.

First are preclinical tests,

which involve experiments
in a laboratory and with animals.

Scientists must ensure

the vaccine candidate
is not only effective, but also safe.

For example, an antibody response
to an imperfect vaccine

could, under extremely rare circumstances,

end up increasing the danger
of becoming infected.

When the potential vaccine achieves
the necessary preclinical results,

clinical trials can begin
in a small group of people.

As the vaccine candidate advances,

it is tested on increasing
numbers of people,

with scientists and doctors

closely monitoring safety,
efficacy and dosing.

Upon successful completion
of clinical trials,

the vaccine candidate
must be reviewed and approved

by regulatory agencies,

such as the FDA,

before large-scale manufacturing
and distribution gets underway

and the licensed vaccine
is administered widely.

Subtitles by Maurício Kakuei Tanaka
Review by Carol Wang